Remdesivir

From monoclonal antibodies to antivirals, this guide has everything you need to know about addressing an infection.
Patient death rates after 28 days were relatively similar for those given remdesivir versus usual care.
Trials found that the anti-viral drug can reduce the recovery time of COVID-19 patients by four days.
The FDA issued emergency approval for the medicine, which may help hospitalized COVID-19 patients recover.
Coronavirus patients around the world have been rushing to join remdesivir studies that opened in hospitals in the last few weeks.